A total of 10 trials involving 71 553 patients in a high-risk cardiac disease study group were included in the analysis.3,4,5,6,7,8,9,10,11,12 A total of 39 053 patients received SGLT2-Is and 32 500 received placebo. This evidence concerns the gene SLC5A2 and heart disorder.